Evidence map›Paper›PMID 37636964›Full record

ArticleACS omega2023

Garbractin A, a Polycyclic Polyprenylated Acylphloroglucinol with a 4,11-dioxatricyclo[4.4.2.0

Xue-Ni Li, Jing Xu, Shuang Yang, Qing-Qing Li, Zheng-Yang Lu, Gui Mei, Jia-Qian Li, Guang-Zhong Yang, Xin-Xiang Lei, Yu Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xue-Ni LiSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, P. R. China.
Jing XuSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, P. R. China.
Shuang YangSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, P. R. China.
Qing-Qing LiSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, P. R. China.
Zheng-Yang LuCollege of Chemistry and Material Sciences, South-Central Minzu University, Wuhan 430074, P. R. China.
Gui MeiSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, P. R. China.
Jia-Qian LiSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, P. R. China.
Guang-Zhong YangSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, P. R. China.ORCID https://orcid.org/0000-0001-9853-5078
Xin-Xiang LeiState Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, P. R. China.ORCID https://orcid.org/0000-0002-5635-5375
Yu ChenCollege of Chemistry and Material Sciences, South-Central Minzu University, Wuhan 430074, P. R. China.
Minzu University of China · CNLanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Garbractin A (

Identifiers

PMID37636964
PMCPMC10448683
OpenAlexW4385809187

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.